31 results found.

Systemic Lupus Erythematosus, or Antiphospholipid Syndrome Clinical Trial

Hospital for Special Surgery, New York - Recruiting 18 years to 45 years.
- Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS).

Lupus Erythematosus, Systemic Clinical Trial using Tabalumab Auto-Injector; Tabalumab Prefilled Syringe

Eli Lilly and Company - Recruiting 18 years or older.
- Pharmacokinetic Evaluations of Tabalumab Following Subcutaneous Administration by Prefilled Syringe or Auto Injector in Patients With Systemic Lupus Erythematosus.
Tabalumab Auto-Injector; Tabalumab Prefilled Syringe

Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic, Lu Clinical Trial using Skin biopsy; Blood collection; Urine collection

Janssen Research & Development, LLC - Recruiting 18 years to 70 years.
- Longitudinal Study of Skin And Systemic Biomarkers In Subjects With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers.
Skin biopsy; Blood collection; Urine collection

Rheumatoid Arthritis, Lupus Erythematosus, Systemic, or Sjogren's Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 24 years or older.
- Agricultural Health Study: Health Follow-up.

Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic, or Clinical Trial using No intervention, skin biopsy; No intervention, blood collection; No intervention, urine collection

Janssen Research & Development, LLC - Recruiting 18 years to 70 years.
- Cross-Sectional Study in Subjects With Active Cutaneous Lupus Erythematosus.
No intervention, skin biopsy; No intervention, blood collection; No intervention, urine collection

Systemic Lupus Erythematosus Clinical Trial using Placebo plus standard therapy; Belimumab 10 mg/kg plus standard therapy; Standard therapy

GlaxoSmithKline - Recruiting 18 years or older.
- A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race With Systemic Lupus Erythematosus (SLE).
Placebo plus standard therapy; Belimumab 10 mg/kg plus standard therapy; Standard therapy

Systemic Lupus Erythematosus Clinical Trial using GSK2586184 50 mg; GSK2586184 100 mg; GSK2586184 200 mg; GSK2586184 400 mg; Placebo

GlaxoSmithKline - Recruiting 18 years to 75 years.
- An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184 in Patients With Mild to Moderate Systemic Lupus Erythematosus.
GSK2586184 50 mg; GSK2586184 100 mg; GSK2586184 200 mg; GSK2586184 400 mg; Placebo

Systemic Lupus Erythematosus Clinical Trial using Placebo plus standard therapy; Belimumab 10 mg/kg plus standard therapy; Standard therapy

GlaxoSmithKline - Recruiting 18 years or older.
- A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab.
Placebo plus standard therapy; Belimumab 10 mg/kg plus standard therapy; Standard therapy

Systemic Lupus Erythematosus (SLE) Clinical Trial using Acthar; Placebo for Acthar

Questcor Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Two-part Study Exploring the Efficacy, Safety, and Pharmacodynamics of Acthar in Systemic Lupus Erythematosus Patients With a History of Persistently Active Disease.
Acthar; Placebo for Acthar

Mixed Connective Tissue Disease (MCTD), or Systemic Lupus Erythem Clinical Trial

University of Miami - Recruiting 18 years or older.
- Immune Response to Small Nuclear Ribonucleoprotein Autoantigens.

Rheumatoid Arthritis, Ankylosing Spondylitis, Systemic Lupus Eryt Clinical Trial using Interleukin 2

Assistance Publique - H“pitaux de Paris - Recruiting 18 years or older.
- Induction of Regulatory t Cells by Low Dose IL2 in Autoimmune and Inflammatory Diseases: a Transnosographic Approach.
Interleukin 2

Systemic Lupus Erythematosus Clinical Trial using Hematopoietic stem cell transplantation

Northwestern University - Recruiting 15 years to 60 years.
- Cyclophosphamide and rATG/Rituximab in Patients With Systemic Lupus Erythematosus: Phase II Trial.
Hematopoietic stem cell transplantation

Lupus Erythematosus, Systemic Clinical Trial using Mycophenolate Mofetil; Hydroxychloroquine or Chloroquine; Prednisone

National Institute of Allergy and Infectious Diseases (NIAID) - Recruiting 18 years to 65 years.
- An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients With Stable, Quiescent Systemic Lupus Erythematosus (SLE).
Mycophenolate Mofetil; Hydroxychloroquine or Chloroquine; Prednisone

SLE Clinical Trial

Ohio State University - Recruiting 18 years to 60 years.
- Myocardial Inflammation in Systemic Lupus Erythematosus.

Lupus Arthritis, Systemic Lupus Erythematosus Clinical Trial using AMG 557; Matching Placebo

Amgen - Recruiting 18 years to 65 years.
- A Randomized, Double-blind, Parallel, Placebo-controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of AMG 557 in Systemic Lupus Erythematosus (SLE) Subjects With Active Lupus Arthritis.
AMG 557; Matching Placebo

Rheumatoid Arthritis, Ankylosing Spondylitis, Lupus Erythematosus Clinical Trial using Employment and Arthritis: Making it Work

University of British Columbia - Recruiting 18 years to 59 years.
- Employment and Arthritis: Making it Work: A Randomized Controlled Trial Evaluating an On-line Program to Help People With Inflammatory Arthritis Remain Employed.
Employment and Arthritis: Making it Work

Systemic Lupus Erythematosus, or Sleep Disorders Clinical Trial using Aerobic Exercise; Control Group

Federal University of Sao Paulo - Recruiting 18 years to 69 years.
- Effectiveness of Exercise Training in Improving Sleep in Patients With Systemic Lupus Erythematosus: A Controlled Randomized Trial..
Aerobic Exercise; Control Group

Lupus Nephritis, or Systemic Lupus Erythematosus Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 10 years or older.
- Studies of the Pathogenesis and Natural History of Systemic Lupus Erythematosus (SLE).

Systemic Lupus Erythematosus Clinical Trial using belimumab 10mg/kg; placebo

GlaxoSmithKline - Recruiting 5 years to 17 years.
- A Multi-center, Randomized, Placebo-Controlled Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Patients With Systemic Lupus Erythematosus.
belimumab 10mg/kg; placebo

Systemic Lupus Erythematosus Clinical Trial using extended release dipyridamole 200mg/aspirin 25mg; 81mg aspirin

Oklahoma Medical Research Foundation - Recruiting 18 years to 70 years.
- Dipyridamole Assessment for Flare Reduction in SLE.
extended release dipyridamole 200mg/aspirin 25mg; 81mg aspirin

Systemic Lupus Erythematosus Clinical Trial using MEDI-546

AstraZeneca - Recruiting N/A or older.
- A Phase 2, Multicenter, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of Intravenous Dose of MEDI-546, a Human Monoclonal Antibody Directed Against Type I Interferon Receptor (IFNAR), in Japanese Subjects With Active Systemic Lupus Erythematosus (SLE).
MEDI-546

Systemic Lupus Erythematosus Clinical Trial using belimumab

GlaxoSmithKline - Recruiting N/A or older.
- Belimumab (BENLYSTAr) Pregnancy Registry (BPR) - Prospective Cohort Study of Pregnancy Outcomes Following Benlysta Exposure Within 4 Months Prior to and/or During Pregnancy.
belimumab

Systemic Lupus Erythematosus Clinical Trial using Allogeneic Stem Cell Transplantation

Northwestern University - Recruiting 18 years to 50 years.
- Allogeneic Stem Cell Transplantation in Patients With Systemic Lupus Erythematosus.
Allogeneic Stem Cell Transplantation

Juvenile Systemic Lupus Erythematosus, or Juvenile Dermatomyositi Clinical Trial using creatine; placebo (dextrose)

University of Sao Paulo - Recruiting 6 years to 18 years.
- Efficacy and Safety of Creatine Supplementation in Patients With Juvenile Systemic Lupus Erythematosus and Juvenile Dermatomyositis.
creatine; placebo (dextrose)

Lupus Erythematosus, Systemic, or Arthritis, Rheumatoid Clinical Trial

Federal University of Sao Paulo - Recruiting 18 years to 60 years.
- Ultrasound Evaluation of Hands in Patients With Systemic Lupus Erythematosus.

Systemic Lupus Erythematosus Clinical Trial using Immunoablation and Autologous Hematopoietic Stem Cell Transplantation

Charite University, Berlin, Germany - Recruiting 18 years to 60 years.
- An Open-Label, Phase II Multicenter Cohort Study of Immunoablation With Cyclophosphamide and Antithymocyte-Globulin and Transplantation of Autologous Cd34-Enriched Hemapoietic Stem Cells Versus Currently Available Immunosuppressive/Immunomodulatory Therapy for Treatment of Refractory Systemic Lupus Erythematosus.
Immunoablation and Autologous Hematopoietic Stem Cell Transplantation

Systemic Lupus Erythematosus Clinical Trial using Depomedrol; Blood drawing only; Methotrexate and depomedrol; Mycophenolate mofetil and depomedrol

Oklahoma Medical Research Foundation - Recruiting 15 years to 70 years.
- Biomarkers of Lupus Disease: Study of Biomarker Changes Before and After Treatment With Depomedrol and Background Medication Withdrawal in Patients With Mild to Moderate SLE Disease Activity.
Depomedrol; Blood drawing only; Methotrexate and depomedrol; Mycophenolate mofetil and depomedrol

Systemic Lupus Erythematosus Clinical Trial

University of Auckland, New Zealand - Recruiting 18 years to 80 years.
- Failure of Cyclophosphamide Therapy in Lupus Nephritis Patients: the Role of Bioactivation Phenotype and Genotype.

Systemic Lupus Erythematosus Clinical Trial

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) - Recruiting N/A or older.
- Lupus Genetic Studies; Lupus Family Registry & Repository.

Refractory Systemic Lupus Erythematosus Clinical Trial using Allogeneic MSC (AlloMSC)

Nanjing Medical University - Recruiting 15 years to 70 years.
- Phase I/IIa: Allogeneic Bone Marrow Derived Mesenchymal Stem Cells Transplantation For Refractory Systemic Lupus Erythematosus.
Allogeneic MSC (AlloMSC)